On November 19, 2019 Pfenex Inc. (NYSE American: PFNX) is a development and licensing biotechnology company reported that focused on leveraging its Pfēnex Expression Technology to develop and improve protein therapies for unmet patient needs (Press release, Pfenex, NOV 19, 2019, View Source [SID1234551471]). Using the patented Pfēnex Expression Technology platform, the Company has developed the FDA-approved PF708 product indicated for the treatment of osteoporosis in certain patients at high risk of fracture and created an advanced pipeline of therapeutic equivalents, biologics and vaccines. The Company announced today that Eef Schimmelpennink, President and Chief Executive Officer, will be presenting at the Evercore ISI HealthCONx Conference 2019 on Tuesday, December 3rd, taking place at the Four Seasons Hotel in Boston, Massachusetts.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Evercore ISI HealthCONx Conference 2019
Date: Tuesday, December 3, 2019
Time: 2:45 p.m. Eastern Time

Interested parties can access the live audio webcast and archive from the Investors Section of Pfenex’s website at www.pfenex.com.